BioCentury
ARTICLE | Clinical News

AMR-001: Additional Phase I data

October 15, 2012 7:00 AM UTC

Additional data from 23 patients in an open-label Phase I trial showed that AMR-001 significantly improved mid-anterior left-ventricular circumferential strain determined by MRI at 3 months vs. baseline (p=0.03), with no further improvement at 6 months vs. 3 months (p=0.34). There was no significant difference vs. baseline in the control group at 3 months (p=0.91) or 6 months (p=0.36). No patients receiving 10 million cells of AMR-001 experienced deterioration in heart muscle function vs. 30-40% of patients in the control arm. Data were published in ISRN Radiology. ...